Sofinnova Investments related stories
All articles and analysis
LabCorp names new addition to board of directorsLabCorp has named Dr. Garheng Kong to its board of directors. The appointment becomes effective December 1, 2013. Dr. Kong is a general partner in Sofinnova Ventures. Based in Burlington, NC, LabCorp is a provider of medical tests that range from routine blood analyses to reproductive genetics to companion diagnostics.
- VC-backed Aerie Pharma prices IPO - Fortune
According to Fortune, Aerie Pharmaceuticals has priced its IPO of 5.25 million shares at between $12 to $14 per share. The company plans to trade the stock on the NASDAQ under the ticker symbol "AERI." RBC Capital Markets and Stifel are acting as lead underwriters. With offices in New Jersey, California and North Carolina, Aerie Pharmaceuticals is a developer of drugs that treat glaucoma patients. The company is backed by Alta Partners, TPG Ventures, Clarus Ventures, Sofinnova Ventures and Osage Ventures.
- Versartis raises $20 mln in Series D financing
Versartis has closed $20 million in Series D financing. Sofinnova Ventures was the lead investor. Return backers Advent Venture Partners' Advent Life Sciences fund, Aisling Capital, Amunix Operating Inc., Index Ventures and New Leaf Venture Partners also participated in this round. In conjunction with the funding Sofinnova's general partner Dr. Srinivas Akkaraju will join Versartis board of directors. Based in Redwood City, Calif., Versartis is a biotechnology company focused on developing treatments for patients with endocrine disorders.
- ABBYY hires VC exec as COO
ABBYY said Tuesday that it has named Peter Meehan as chief operating officer. Prior to joining the company, Meehan worked as a venture advisor for Sofinnova Ventures. Headquartered in Moscow, ABBYY is a provider of document recognition, capture and linguistic technologies and services.
Fund performance: CalSTRS revs up its venture portfolioThe California State Teachers’ Retirement System adds six new VC funds in 2011 and 2012; sees nice gains in Giza and Shasta funds
Venture Capital Warms to European BiotechsThe U.S. IPO boom offers a route for some, as some biotechs in Switzerland have attracted about $80 million in VC funding so far this year
Venture Capital Warms to European BiotechsPrivate biotech companies globally raised almost $1.3 billion through venture capital deals in the second quarter, up 190 percent from Q1, and European biotechs grabbed 44 percent of that total, according to a report.
- Sofinnova Ventures Makes James a Partner
Sofinnova Ventures said Tuesday that Jennifer James was promoted to partner. James managed investor relations through Sofinnova’s most recent fundraising effort for SVP VIII, a $440M life science focused fund. James joined Sofinnova as VP of Marketing and Investor Relations in 2011.
- Crocus Technology Secures $45m Series D
Crocus Technology, a developer of magnetically enhanced semiconductor technologies for mobile security, embedded microcontrollers, harsh environment electronics and magnetic sensors, has raised 34 million euros ($45 million) in additional capital. A new private investor, Industrial Investors, joined the round led by Idinvest Partners. Major investors Sofinnova Ventures, Innovation Capital, Nanodimension and Ventech also participated.
- Eliadis Joins Lux Capital
Karen Eliadis has joined Lux Capital as its CFO based in Palo Alto. Eliadis was most recently the Chief Financial Officer of BlueRun Ventures.